Site icon Alpha Edge Investing

Sage Therapeutics (SAGE)

Second quarter 2021 earnings released: US$1.83 loss per share (vs US$2.63 loss in 2Q 2020)

The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses.Second quarter 2021 results:

Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.

Exit mobile version